Literature DB >> 3882744

Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology.

M M Levine, C R Young, R E Black, Y Takeda, R A Finkelstein.   

Abstract

Serum immunoglobulin G antibodies to purified heat-labile enterotoxin (LT) from human (LTh) and porcine (LTp) Escherichia coli strains and cholera enterotoxin (CT) were measured by an enzyme-linked immunosorbent assay. Sera from patients with LTh E. coli infection showed a prominent response with LTh, an intermediate response with LTp, and a meager response with CT. Of 47 persons with clinical LTh-producing E. coli (herein shortened to LTh E. coli) infections, significant rises in antitoxin were detected against LTh in 36 (77%), against LTp in 30 (64%), and against CT in only 13 (28%) patients; seroconversions also occurred in 11 of 14 (79%) patients with subclinical LTh E. coli infections. In North Americans with experimental LTh E. coli infection, anti-Lth did not remain at high levels for more than 3 months. Persons with cholera manifested antitoxin responses that were similarly potent against all three toxin antigens; in fact, net optical density values were often slightly higher against LTh than against CT. The ratio of CT/LTh ELISA net optical density in convalescent sera proved to be a sensitive means to differentiate LT E. coli from cholera infection. All 11 cholera patients tested had CT/LTh ratios of greater than 0.70, whereas in only 1 of 47 LTh E. coli infections did the ratio exceed that value (it was 0.71) (P less than 0.0000000001). In single serum specimens, a net optical density of greater than or equal to 0.30 against LTh was shown to be a useful cutoff in screening sera for recent LTh E. coli or past cholera infection. The CT/LTh ratio was then used to differentiate definitively. Sera from healthy 3- to 5-year -olds and 15- to 19-year-olds in Maryland, Chile, and Bangladesh were tested against LTh and CT. The serological results fit known epidemiological observations. (i) LTh infections are rare in the United States (only 2 of 60 sera had LTh net optical density values of >/= 0.30. (ii) In contrast, evidence of recent LTh E. coli infections was very common in Chilean (69%) and Bangladeshi (57%) 3- to 5-year-olds and not uncommon in 15- to 19-year-olds (38 and 31%, respectively) in those countries. (iii) Only Bangladeshi sera showed serological evidence of cholera infections (CT/LTh ratios of > 0.70). The immunoglobulin G enzyme-linked immunosorbent assay measuring antibodies to purified LTh and CT represents a practical and effective tool for the serological study of LTh E. coli and cholera diarrheal infections.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3882744      PMCID: PMC271608          DOI: 10.1128/jcm.21.2.174-179.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Antibodies to heat-labile Escherichia coli enterotoxin in Apaches in Whiteriver, Arizona.

Authors:  R B Sack; N Hirschborn; W E Woodward; D A Sack; R A Cash
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

2.  Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin.

Authors:  M M Levine; E S Caplan; D Waterman; R A Cash; R B Hornick; M J Snyder
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

3.  Epidemic diarrhea at Crater Lake from enterotoxigenic Escherichia coli. A large waterborne outbreak.

Authors:  M L Rosenberg; J P Koplan; I K Wachsmuth; J G Wells; E J Gangarosa; R L Guerrant; D A Sack
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

4.  Enterotoxin antibodies in relation to diarrhoea in Swedish soldiers in Cyprus.

Authors:  A M Svennerholm; E Bäck; J Holmgren
Journal:  Bull World Health Organ       Date:  1977       Impact factor: 9.408

5.  Humoral immune response to the heat-labile enterotoxin of Escherichia coli in naturally acquired diarrhea and antitoxin determination by passive immune hemolysis.

Authors:  D J Evans; G Ruiz-Palacios; D E Evans; H L DuPont; L K Pickering; J Olarte
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

6.  Immunological study of the heat-labile enterotoxins of Escherichia coli and Vibrio cholerae.

Authors:  C L Gyles
Journal:  Infect Immun       Date:  1974-03       Impact factor: 3.441

7.  Comparison of the tissue receptors for Vibrio cholerae and Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoid.

Authors:  J Holmgren
Journal:  Infect Immun       Date:  1973-12       Impact factor: 3.441

8.  Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. II. Incidence of diarrhea and association with known pathogens.

Authors:  R E Black; K H Brown; S Becker; A R Alim; I Huq
Journal:  Am J Epidemiol       Date:  1982-03       Impact factor: 4.897

9.  Antibodies to heat-labile Escherichia coli enterotoxins in human milk and sera. A study of Ethiopian and Swedish mothers and their children.

Authors:  A Aust-Kettis; M Gebre-Medhin; D Habte; N Khosla; T Wadström
Journal:  Trop Geogr Med       Date:  1981-09

10.  Immunological differences among the cholera/coli family of enterotoxins.

Authors:  B A Marchlewicz; R A Finkelstein
Journal:  Diagn Microbiol Infect Dis       Date:  1983-06       Impact factor: 2.803

View more
  32 in total

1.  Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Authors:  D N Taylor; J L Sanchez; J M Castro; C Lebron; C M Parrado; D E Johnson; C O Tacket; G A Losonsky; S S Wasserman; M M Levine; S J Cryz
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

Authors:  K L Kotloff; S S Wasserman; S O'Donnell; G A Losonsky; S J Cryz; M M Levine
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

3.  Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults.

Authors:  S J Cryz; M M Levine; G Losonsky; J B Kaper; B Althaus
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

4.  Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors:  Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

5.  Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection.

Authors:  C O Tacket; R K Taylor; G Losonsky; Y Lim; J P Nataro; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

6.  Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

Authors:  D N Taylor; C O Tacket; G Losonsky; O Castro; J Gutierrez; R Meza; J P Nataro; J B Kaper; S S Wasserman; R Edelman; M M Levine; S J Cryz
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

7.  Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.

Authors:  S Migasena; P Pitisuttitham; B Prayurahong; P Suntharasamai; W Supanaranond; V Desakorn; U Vongsthongsri; B Tall; J Ketley; G Losonsky
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

8.  Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103.

Authors:  J M Ketley; J B Kaper; D A Herrington; G Losonsky; M M Levine
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

9.  Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques.

Authors:  M M Levine; J B Kaper; D Herrington; G Losonsky; J G Morris; M L Clements; R E Black; B Tall; R Hall
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

10.  Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin.

Authors:  R E Black; M M Levine; M L Clements; C R Young; A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.